This ETF's Trouncing the S&P 500 by 10 Percentage Points in 2026, and It Can Keep Outperforming

The Schwab U.S. Dividend Equity ETF (SCHD) is up 14.1% year to date, well ahead of the S&P 500's 4.2% total return and the Vanguard Value ETF's 7.5%. The article argues that SCHD's quality screens and dividend-growth focus have produced a portfolio of high-quality value stocks spanning energy, consumer staples, healthcare, and industrials. It also cites supportive macro drivers including AI-related capital spending, lower interest rates, pro-business tax/regulatory policy, and still-cheap valuation versus growth stocks.

Analysis

The real edge here is not “dividends” but factor purity: the basket concentrates on businesses with self-funding balance sheets and visible cash conversion, which makes it behave more like a quality/capital-allocation ETF than a classic value sleeve. In this regime, the market is paying for duration in cash flows and punishing capex-heavy growth, so names tied to energy infrastructure, healthcare cash generation, and defensive staples should continue to win on relative revisions even if the broad market flatlines.

The second-order beneficiary is the supplier ecosystem around AI and reindustrialization, not the hyperscalers themselves. If AI capex stays elevated, the incremental spend flows into power, equipment, and midstream/logistics rather than into the software complex; that creates a multi-quarter tailwind for the highest-cash-flow producers in CVX/COP and for industrial input providers indirectly, while leaving growth valuation leadership structurally challenged.

The biggest risk to the trade is not a macro slowdown, but a rapid rotation back into mega-cap growth if rates fall faster than expected or AI spending becomes more monetizable than feared. In that case, the “quality value” premium compresses quickly because these stocks have already rerated on defensive ownership; the ETF can underperform for weeks at a time if the market starts rewarding long-duration earnings again. The contrarian point is that the valuation gap is wide, but not all cheap is mispriced: some of these names are cheap because their growth is genuinely low, so sustained outperformance likely depends on continued capital-return discipline and stable policy rather than multiple expansion alone.

Key Decisions for Investors

• Long SCHD vs short QQQ on a 3-6 month horizon: express the view that cash-flow quality and capital return outperform long-duration growth while rates stay rangebound; target 8-12% relative upside with a 4-5% stop if mega-cap growth reaccelerates.
• Overweight CVX/COP over broad energy ETFs for the next 2 quarters: these names should capture the highest free-cash-flow sensitivity to resilient upstream activity and still offer downside support from dividends/buybacks; prefer entry on any 3-5% pullback.
• Pair long HD/PEP against short a basket of software software/AI-adjacent high-multiple names: the trade benefits if consumer balance sheets stay intact and AI capex keeps favoring real-economy spend; risk is a sharp growth rally or wage-driven margin pressure.
• Use UNH as a quality core long only on weakness, not momentum chase: healthcare is likely to remain a relative defensive winner, but regulatory headline risk can create 5-8% drawdowns that are better used as entry points.
• Avoid chasing TXN/VZ as ‘cheap’ income names until rates roll over further: the market is already comfortable with their yield profiles, so upside is more limited unless earnings revisions inflect; better risk/reward exists in higher-quality cyclicals within the same factor sleeve.